Drug Development

Rare disease drug development is a race against time, driven by innovation and compassion. This page highlights articles regarding groundbreaking research, clinical trials, and regulatory milestones shaping the future of treatments. Learn how scientists, pharmaceutical companies, and patient communities collaborate to turn hope into healing for those living with rare diseases.

More

3D Printed Treatment Options | The CheckRare Brief

In this episode, we discuss a new formulation of treatment for HAE, the FDA approval of Voceryq for recurrent respiratory papillomatosis, and 3D printed treatment options.       New...

Ultragenyx Gets $203M in Second Priority Review Voucher This Month | The CheckRare Brief

On this episode, we discuss the FDA approval of Enspryng for TED, the new FDA Rare Disease Framework Initiative, Ultrangenyx’s second sold PRV this month, and using AI to reduce diagnostic delays....

Therapies for MCT8 Deficiency and Nephrotic Syndrome Get FDA Approval | The CheckRare Brief Ep 10

On September 28th, the FDA approved Emcitate, or tiratricol, from Egetis Therapeutics. It's the first-ever treatment for MCT8 deficiency, a condition also known as Allan-Herndon-Dudley syndrome. ...

FDA CDER’s Accelerating Rare Disease Cures Program

Paz Vellanki, MD, PhD, Vice President of Clinical Development at Precision for Medicine, discusses the FDA CDER’s Accelerating Rare Disease Cures (ARC) Program.    The ARC Program was launched...

Recent Videos

Syndax REVEAL Clinical Trial Banner
Biomarkers and Beyond: Integrating AI in Rare Disease Management

Biomarkers and Beyond: Integrating AI in Rare Disease Management

Staci Kallish, DO, Clinical Geneticist at Penn Medicine in Philadelphia, is helping to lead a new wave of innovation at the intersection of artificial intelligence (AI) and rare disease care.